This CPB is revised to state that bortezomib is considered medically necessary as the second-line treatment of persons with relapsed or refractory peripheral T-cell lymphoma who are not candidates for high-dose chemotherapy and autologous stem cell transplant. This policy revision is supported by guidelines from the National Comprehensive Cancer Network.